New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 9, 2024 - The FDA announced the approval of ARS Pharmaceuticals neffy (epinephrine), for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater.
Download PDF
Return to publications
